Depression Clinical Trial
Official title:
An Investigation Examining the Evidence for Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder
NCT number | NCT00327756 |
Other study ID # | 060162 |
Secondary ID | 06-M-0162 |
Status | Withdrawn |
Phase | Phase 2 |
First received | May 18, 2006 |
Last updated | November 22, 2011 |
Start date | May 2006 |
This study will examine whether mitochondrial function is impaired in patients with bipolar
disorder. Mitrochondria are small organelles inside the cell that are responsible for energy
production. Recent studies in animals and humans suggest that abnormalities of mitrochondria
may be involved in bipolar depression. The study will also examine whether the food
supplement Coenzyme Q10 (CoQ10) improves mitochondrial function and symptoms such as
depressed mood, low energy, anxiety or slowness in thinking and movements in bipolar
patients. CoQ10 has been used to increase cell energy production and as an antioxidant. It
has had some benefit in patients with Parkinson's disease and migraine and in prolonging
survival in patients with cancer and heart failure.
Patients 18-65 years of age with bipolar disorder who are currently in a depressive episode
of at least 4 weeks duration may be eligible for this study. The study has four phases, as
follows:
Phase I: Medication Withdrawal
Patients taper off all psychotropic medications, usually over 1 to 2 weeks.
Phase II: Baseline Evaluation
After being off all medication for about 2 weeks, patients undergo the following procedures:
- Magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS). The two
procedures are performed in an MRI scanner. Both tests use a strong magnetic field and
radio waves to obtain images that provide information on brain anatomy and chemistry.
- Blood tests to assess mitochondrial function isolated from blood cells.
- Skin biopsy for tests of mitochondria. A small sample of skin tissue 5 x 5 millimeters
is surgically removed.
Phase III: Administration of CoQ10 or Placebo
Participants are randomly assigned to take either CoQ10 or placebo (an inactive look-alike
substance) twice a day by mouth. While taking the study medication, patients have the
following procedures periodically:
- Rating scales for anxiety and depression and adverse events.
- Check of vital signs.
- Blood and urine sample collections.
Phase IV: Study Completion
At the end of the 8 weeks of treatment, patients have a physical examination and
electrocardiogram, and the procedures in phase II are repeated. Participants may then
receive short-term treatment (up to 12 weeks) with medications for bipolar depression,
followed by referred to a community physician for long-term treatment.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | May 2009 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
- INCLUSION CRITERIA: - Male or female subjects, 18 to 65 years of age. - Female subjects of childbearing potential must be using a medically accepted means of contraception. - Each subject must understand the nature of the study and must sign an informed consent document. - Subjects must fulfill the criteria for Bipolar disorder depressed without psychotic features including rapid cycling as defined in DSM-IV based on clinical assessment and confirmed by structured diagnostic interview SCID-P. - Subjects must have an initial score at Visit 1 and Visit 2 of at least 16 on the MADRS - In bipolar II disorder, subjects must have experienced, in the opinion of the investigator, at least two previous hypomanic and two major depressive episodes as defined in DSM-IV. - Current major depressive episode at least 4 weeks in duration. EXCLUSION CRITERIA: - Subjects who are currently on a mood stabilizer for maintenance treatment and are benefiting from it. - Current diagnosis of primary anxiety disorder necessitating treatment (subjects with OCD will be excluded). - Presence of psychotic features - Participation in a clinical trial of another investigational drug within 1 month prior to study entry (Visit 1). - Female subjects who are either pregnant or nursing. - Serious, unstable illnesses including hepatic, renal, gastroenterological, respiratory, cardiovascular (including ischemic heart disease), endocrinology, neurological, immunologic, or hematological disease. - Subjects diagnosed with a mitochondrial disorder. - Subjects taking other putative mitochondrial enhancers (e.g., vitamin E, carnitine, creatine, Vit complex B, pramipexole; see Appendix B) by the time of randomization (Visit 2). - Subjects taking Statins - Subjects with Diabetes Mellitus (Type I and Type II) - Subjects with a history of clotting disorders or needing anticoagulants e.g. warfarin. - Subjects with history of deep vein thrombosis or the following risk factors for DVTs, smoking and/or contraceptives (30 days before Visit 2). - Subjects with uncorrected hypothyroidism or hyperthyroidism. - Subjects with one or more seizures. - Documented history of hypersensitivity or intolerance to CoQ10. - DSM-IV substance abuse (except caffeine) within the past 12 months, 1 month for nicotine. - DSM-IV lifetime substance dependence (except caffeine). - Treatment with an injectable depot neuroleptic within less than one dosing interval prior to Visit 2. - Treatment with a reversible MAOI, guanethidine, or guanadrel within 1 week prior to Visit 2. - Treatment with fluoxetine within 6 weeks prior to Visit 2. - Treatment with any other concomitant medication 1 day prior to Visit 2. - Treatment with clozapine or ECT within 1 month prior to Visit 2. - Judged clinically to be at serious suicidal risk. Healthy Control Sample: Twenty-six subjects (ages 18-65) who do not meet criteria for any major medical or psychiatric disorder (using SCID -NP) will undergo imaging and mitochondrial assay part of the study and serve as control group. Control subjects will be matched to bipolar subjects for age, gender, Body Mass Index (BMI) plus or minus 2. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Mental Health (NIMH) |
United States,
Arias-Mendoza F. In vivo magnetic resonance spectroscopy in the evaluation of mitochondrial disorders. Mitochondrion. 2004 Sep;4(5-6):491-501. Epub 2004 Sep 30. — View Citation
Baker SK, Tarnopolsky MA. Targeting cellular energy production in neurological disorders. Expert Opin Investig Drugs. 2003 Oct;12(10):1655-79. Review. — View Citation
Bertolino A, Frye M, Callicott JH, Mattay VS, Rakow R, Shelton-Repella J, Post R, Weinberger DR. Neuronal pathology in the hippocampal area of patients with bipolar disorder: a study with proton magnetic resonance spectroscopic imaging. Biol Psychiatry. 2003 May 15;53(10):906-13. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Compare brain lactate levels between healthy controls and subjects with bipolar depression and assess in subjects w/bipolar depression the effect of of CoQ10 admin compared to placebo on the brain lactate signal obtained w/MRS w/photic stimulation. | 8 weeks | No | |
Secondary | To determine the antidepressant efficacy of CoQ10 compared to placebo in depressed subjects w/bipolar disorder by using the mean change in MADRS total score pre- and post-study. | 8-weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A |